Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02544633 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET
A Phase 2 study, sponsored by Mirati Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT02544633 is a Phase 2 study that has completed, run by Mirati Therapeutics. The registered enrollment target is 68 participants.
The verdict
NCT02544633, a Phase 2 study, has completed, sponsored by Mirati Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
MGCD265 is an orally administered receptor tyrosine kinase inhibitor that targets MET and other receptors. This study is a Phase 2 trial of MGCD265 in patients with locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) that has activating genetic changes of the MET gene (mutation or amplification \[increase number of gene copies\]). Testing for tumor gene changes can be performed in tumor tissue or blood samples. Patients must have previously received treatment with chemotherapy. The number of patients to be enrolled will depend on how many enrolled patients experience tumor size reduction. MGCD265 will be administered orally, twice daily. The study is designed to evaluate whether the number of patients experiencing tumor size reduction is substantially higher than would be expected with other available treatments.
Interventions
- DRUG MGCD265
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2015-10 |
| Est. Completion | 2019-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02544633
The ClinicalTrials.gov registry entry for NCT02544633 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MGCD265 is the first listed.
NCT02544633 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02544633 about?
NCT02544633 is a clinical study titled "Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET". MGCD265 is an orally administered receptor tyrosine kinase inhibitor that targets MET and other receptors. This study is a Phase 2 trial of MGCD265 in patients with locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) that has activating genetic changes of the MET gene (mu...
What is the current status of trial NCT02544633?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2015-10. Estimated completion is 2019-01.
What interventions are being tested in trial NCT02544633?
The interventions under investigation include: MGCD265 (DRUG).
Who is sponsoring clinical trial NCT02544633?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.